Stay updated with breaking news from Intermediate Risk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.
Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.
First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals' Lead Immunotherapy ISA101b with Keytruda® Combination aimed at priming and driving durable patient immune responses to cancer News provided by Share this article Share this article LEIDEN, The Netherlands, Jan. 26, 2021 /PRNewswire/ -- ISA Pharmaceuticals B.V., a clinical-stage company dedicated to developing rationally designed immunotherapeutics for oncology and infectious disease, today announced that the first patient has been dosed with its lead product ISA101b in a Phase II trial conducted and sponsored by UPMC...
(1) Combination aimed at priming and driving durable patient immune responses to cancer LEIDEN, The Netherlands, Jan. 26, 2021 /PRNewswire/ -- ISA Pharmaceuticals B.V., a clinical-stage company dedicated to developing rationally designed immunotherapeutics for oncology and infectious disease, today announced that the first patient has been dosed with its lead product ISA101b in a Phase II trial conducted and sponsored by UPMC Hillman Cancer Center, the University of Pittsburgh, PA, and supported by Merck Sharp & Dohme Corp and ISA Pharmaceuticals B.V. The study in previously untreated patient...